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The aim of the study was to evaluate proton magnetic resonance spectroscopy (
1H MRS) for noninvasive biological characterisation
of neuroblastoma xenografts in vivo. For designing the experiments, human neuroblastoma xenografts growing subcutaneously in
nude rats were analysed in vivo with
1H MRS and magnetic resonance imaging at 4.7T. The effects of spontaneous tumour growth
and antiangiogenesis treatment, respectively, on spectral characteristics were evaluated. The spectroscopic findings were compared
to tumour morphology, proliferation and viable tumour tissue fraction. The results showed that signals from choline (Cho)-containing
compounds and mobile lipids (MLs) dominated the spectra. The individual ML/Cho ratios for both treated and untreated tumours
were positively correlated with tumour volume (Po0.05). There was an inverse correlation between the ML/Cho ratio and the
viable tumour fraction (r¼ 0.86, Po0.001). Higher ML/Cho ratios concomitant with pronounced histological changes were seen in
spectra from tumours treated with the antiangiogenic drug TNP-470, compared to untreated control tumours (Po0.05). In
conclusion, the ML/Cho ratio obtained in vivo by
1H MRS enabled accurate assessment of the viable tumour fraction in a human
neuroblastoma xenograft model.
1H MRS also revealed early metabolic effects of antiangiogenesis treatment.
1H MRS could prove
useful as a tool to monitor experimental therapy in preclinical models of neuroblastoma, and possibly also in children.
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Treatment with cytotoxic and cytostatic agents in addition to
surgery is the cornerstone of clinical therapy for childhood solid
tumours. Alteration in tumour size, assessed by magnetic
resonance imaging (MRI), computed tomography (CT) or ultra-
sound, is currently the basis for the evaluation of treatment
response (Berdon et al, 1992; Hiorns and Owens, 2001). This
evaluation is usually performed after weeks or months of
treatment, during which the child may suffer from severe side
effects and not always benefit from the therapy.
The development of sensitive methods for repeated and
noninvasive measurement of tumour biological activity during
treatment needs to be attempted in order to optimise and
individualise the treatment of childhood solid tumours. MRI is
currently the method of choice for radiological evaluation of many
childhood tumours and is increasingly used in clinical routine
(Finelli et al, 2000; Shapeero and Vanel, 2000; Siegel et al, 2002). It
is easily accessible in most paediatric cancer centres, considered
safe and generally well tolerated.
The use of proton magnetic resonance spectroscopy (
1H MRS)
can complement MRI in useful ways.
1H MRS allows sampling of
detailed biochemical information from normal tissues or patho-
logical processes and has proved valuable for the characterisation
of a wide range of malignant disorders (Negendank, 1992).
1H MRS
shares many similarities with conventional MRI (for basic
principles of
1H MRS and MRI, see previously published reviews
(Howe et al, 1993; de Certaines, 1996)). Using
1H MRS, metabolic
information is obtained by suppressing the water contribution to
the received echo followed by frequency analysis of the remaining
signal. Individual molecules may thus be identified based on their
inherent individual frequency fingerprints (chemical shift from
water). A molecular configuration that enables a high level of
proton mobility is a prerequisite for detection with
1H MRS.
Accessible metabolites include a large number of intracellular
compounds such as phospholipids and polypeptides.
Metabolites with chemical shifts between 0.9 and 1.4ppm are
frequently observed in
1H MRS spectra of human tumours
(Guidoni et al, 1987; Le Moyec et al, 1992; Negendank et al,
1996). These signals principally correspond to fatty acyl chains
with methylene (CH2) and methyl (CH3) groups, and are
commonly designated mobile lipids (MLs). Several reports indicate
a possible correlation between the amount of MLs and tumour cell
death (Kuesel et al, 1994, 1996). Choline-(Cho) containing
compounds (chemical shift¼3.2ppm) are abundant during
the synthesis and degradation of cellular membranes. As
Received 15 July 2002; revised 7 October 2002; accepted 7 October
2002
*Correspondence: Dr P Kogner, Childhood Cancer Research Unit,
Department of Woman and Child Health, Karolinska Institutet, Karolinska
Hospital, S-171 76 Stockholm, Sweden; E-mail: Per.Kogner@ks.se
British Journal of Cancer (2003) 88, 478–485
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sCho-containing compounds are characteristically elevated in many
malignant tumours their relative signal intensity has been
suggested as an indicator of grade of malignancy (Usenius et al,
1994; Tedeschi et al, 1997).
Neuroblastoma, an embryonal tumour of the sympathetic
nervous system, is the most common extracranial solid tumour
in children. The clinical course is highly heterogeneous ranging
from spontaneous involution (as sometimes seen in infants) to
rapid tumour dissemination and a dismal prognosis in the
majority of older children. Metastases to bone or bone marrow
or the finding of certain specific genetic aberrations (e.g. MYCN
amplification, 1p deletion, 17q gain) (Seeger et al, 1985; Caron et al,
1996; Bown et al, 1999) in the tumour cells are major adverse
prognostic factors. For these patients long-term survival is seldom
achieved despite intensive multimodal treatment (Matthay et al,
1999). The availability of repeated noninvasive assessment of
treatment response could contribute to improved outcome for
children with high-risk neuroblastoma by early evaluation of novel
therapy and application of individualised treatment.
In the present work, we employed a xenograft model of human
neuroblastoma in an attempt to evaluate the biological relevance of
metabolites detected by
1H MRS in vivo. In particular, we
investigated Cho and MLs. We were able to show a significant
inverse correlation between the ML/Cho ratio and the viable
tumour fraction. Compared to untreated controls, tumours treated
with an angiogenesis inhibitor showed higher ML/Cho ratios
concomitant with marked histological changes at a time point
when tumour volumes were still unaffected by treatment.
MATERIALS AND METHODS
Neuroblastoma cells
The human neuroblastoma cell line SH-SY5Y (was kindly provided
by Dr June Biedler, New York) (Biedler et al, 1973). Cells were
cultured at 371C in a humidified 95% air/5% CO2 atmosphere.
Eagle’s minimum essential medium was supplemented with 10%
foetal bovine serum, L-glutamine 2mM, penicillin G 100IUml
 1
and streptomycin 100mgml
 1 (Gibco BRL, Paisley, Scotland, UK).
The medium was changed twice weekly and confluent cultures
were subcultivated after treatment with 0.5gl
 1 trypsin and
0.2gl
 1 EDTA (Gibco BRL). Cultures were free from mycoplasma
as verified by DNA staining. For xenotransplantation, a single-cell
suspension, approximately 10
8cellsml
 1, was prepared in culture
medium supplemented with L-glutamine (2mM). The viability and
exact cell concentration were assessed by trypan blue dye
exclusion using a haematocytometer.
Animal model
A total of 20 male nude rats (HsdHan: RNU-rnu, Harlan,
Netherlands) at the age of 5–6 weeks were used for the
establishment of xenografts as previously described (Nilsson et al,
1993). In short, animals were anaesthetised with Hypnorm
(Janssen Pharmaceutical, Beerse, Belgium) and 2 10
7 cells
suspended in 0.2ml medium were injected into each hind limb.
A 23-gauge cannula was used to deposit the suspension
subcutaneously (s.c.). Attention was paid so as not to pierce the
muscle fascia or lose cells by leakage from the injection site.
Ethics
The experiments described herein were approved by the Regional
Ethics Committee for Animal Research. They also meet the ethical
standards required by the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR, 1998) Guidelines.
Quantification of tumour growth
Tumour take was defined as the observation of a palpable and
measurable nodule in the area of cell injection. Tumours were
measured with a digital calliper every other day and tumour
volume was calculated by length width
2 0.44 (Wassberg et al,
1997). Tumours were allowed to reach a maximum length of
25mm. Tumours were detectable in 18 out of 20 rats within 10–20
days after cell inoculation and grew with a doubling time of 3–5
days. Animals without tumour take were excluded from the study.
TNP-470-treated animals were followed for 10 days and the
tumour volumes at day 10 were 1.1570.56ml (mean7s.d.), n¼8,
range 0.74–2.4ml. Control animals were killed at different time
points (days 4–21) with final tumour volumes of 3.472.9ml
(mean7s.d.), n¼9, range 0.4–8.6ml. In this group, the two
largest tumours were followed up to a size of approximately
25mm, which represented days 19 and 21 from tumour take,
respectively.
Experimental treatment
Animals were randomly assigned to either control (n¼10) or
treatment group (n¼8). Animals in the treatment group received
the antiangiogenic compound TNP-470 (kindly provided by Dr
Rolf Christofferson, Uppsala) 10mgkg
 1 s.c. every other day for 10
days (Wassberg et al, 1997). Control animals received no
treatment.
Magnetic resonance imaging and,
1HM R S
MRI examinations were performed using a 4.7T magnet with
horizontal bore (Bruker Biospec Avance 47/40, Bruker, Karlsruhe,
Germany). The magnet was equipped with a 12cm inner diameter
self-shielded gradient system (max. gradient strength
200mTm
 1). Tumours were investigated using a circular surface
coil with a planar circular detection area of 3cm. The surface coil
was fitted into a customised Plexiglas rig placed in the centre of the
gradient system. In order to facilitate the positioning, the rat was
placed on a separate rig in side position. Animals were
anaesthetised with isofluorane and respiratory activity was
monitored continuously. Body temperature was registered and
maintained at 3770.51C with a heated air stream. The manufac-
turer’s implementation of RARE sequence was used for anatomical
imaging, with the following parameters: T1-weighted images:
repetition time (TR)¼535ms, echo time (TE)¼10ms; T2-
weighted images: TR¼2500ms, TE¼115ms; proton density-
weighted images: TR¼2500ms, TE¼35ms.
For MRS, the STEAM sequence, which uses three lobe sinc
pulses, was employed for selection of volumes of interest (VOIs)
and additional spoiling gradients. VOIs were carefully inscribed
within the xenografts to avoid spectral contamination from
adjacent muscle or fatty tissue. The VOI was chosen to include a
maximal volume of the tumour, and thus varied with tumour size
between approximately 0.2 and 6cm
3. Care was taken so that the
included volumes were as representative as possible for the whole
tumour appearance as viewed in MRI. In a few cases, shimming
difficulties lead to the choice of somewhat smaller volumes. The
VOI approximately represented 50–80% of the total tumour
volume.
After suppression of the water signal, acquisitions were averaged
(64–128) until a signal-to-noise ratio sufficient for spectral
evaluation was reached. A long TR (6s) was employed in order
to achieve full relaxation between scans and to avoid different
degrees of saturation because of differences in T1 and spatial
variation of the excitation flip angle. The TE was varied to
differentiate between the trimethyl singlet of Cho-containing
compounds (chemical shift¼3.22ppm), multiple of macromole-
cules/lipid resonances (ML) and weakly coupled lactate (Lac,
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s1.33ppm). The first spectrum was recorded at 135ms, where the
slowly relaxing Cho is preserved and Lac is inverted. If a residual
signal of fast relaxing lipids was present, the measurement was
repeated at TE¼270ms to improve the relaxation differentiation.
Finally, a spectrum at short TE¼20ms was recorded showing all
metabolites with negligible T2 weighting. In addition, spectra from
skeletal muscle and subcutaneous fat were recorded to identify
corresponding contamination. This was found to be negligible. The
metabolic levels were estimated by peak area integration after
appropriate baseline correction. For calculation of the ML/Cho
ratio, the methylene lipid peak appearing at 1.2–1.4ppm (TE¼20)
was employed.
In the control group, MRI/MRS was performed at time points
between days 4 and 21 from tumour take in order to study the
influence of tumour volume on spectroscopic characteristics. In
the treatment group MRI/MRS was performed after completion of
therapy (day 1071). In both groups, there was a sufficient
variation of tumour size such that spectroscopic measurements
could be correlated to the volumes. On the day of MR-
examination, the tumour volume was measured as described.
Morphology and assessment of tumour viability
Animals were killed by an overdose of pentobarbital immediately
after the MRS examination. Tumours were excised, fixed in 10%
formalin and embedded in paraffin. Sections (5mm) were obtained
from different parts of each tumour and processed for histology.
Tumour cell proliferation was assessed using a rabbit monoclonal
antibody raised against the tumour proliferation marker Ki-67 (Ki-
67, rabbit anti-human, A047. Dakopatts, Stockholm, Sweden). A
Ki-67 labelling index (LI) was calculated from 1500 nuclei at a
magnification of  400 in three randomly chosen viable areas. The
terminal deoxynucleotidyl transferase (TUNEL) reactivity assay
(ApopTag, S7100, Intergen, NY, USA) was employed for quanti-
fication of apoptosis (Gavrieli et al, 1992). Haematoxylin–eosin
(HE) staining was used for routine morphology. The Scion Image
computer software package (Scion Corp.) was employed for
calculating necrotic/apoptotic areas and viable tumour areas,
respectively. The overall tumour viability was estimated by
calculating the surface areas of viable regions in three different
randomly chosen longitudinal tumour sections (at least one
section being close to the centre of the tumour). The viable
tumour fraction was expressed as the mean value of these
measurements in percent for each individual tumour. For cells to
be classified as viable, findings of well-defined borders and intact
nuclei were obligate. An investigator blinded to treatment status
and MRS results performed the morphological evaluation.
Statistical analysis
Statistical analysis was performed using appropriate software
(SYSTAT, Inc., Evanston, IL, USA). Parameters were correlated to
tumour volume or viable tumour fraction in univariate regression
models and the Pearson correlation factors were calculated. For
comparison between different groups, t-values were calculated as
previously described (Evtouchenko et al, 1996) and compared to
the critical value, t* of the Student’s distribution at 1 q
(0.975).
RESULTS
MRI and
1HM R S
Tumours o1.5ml generally appeared homogeneous but occasion-
ally contained foci with low signal intensity on T2 images. Such
low signal areas were seen more often in larger tumours. All
tumours 42ml had a heterogeneous appearance, containing both
hyperintense and hypointense areas (Figure 1).
In MR spectroscopy, short TE spectra (TE¼20ms) were
dominated by signals from Cho at 3.2ppm and ML signals, the
latter contributing to resonances at 0.7–0.9ppm and 1.2–1.5ppm,
respectively (Figures 1 and 2).
Spectra from small xenografts (Vo1.5ml) typically had intense
Cho signals together with moderate ML levels (Figure 1b). A small
peak at 3.0ppm, compatible with creatine/phosphocreatine,
seemed to be present in most tumours but could not be
unequivocally separated from Cho and was therefore not analysed
further. The putative neuronal marker NAA (N-acetyl-aspartate)
(Urenjak et al, 1992) with a chemical shift of 2.0ppm was not
distinguishable at short TEs where lipid signals overlapped with
this spectral region. Neither intermediate (TE¼135ms) nor long
(TE¼172ms) TEs (where lipid signals are fully relaxed) could
support any presence of NAA in the xenografts (Figure 2). Spectra
obtained from large tumours (V42ml) generally displayed a ML
peak of high intensity at 1.2–1.4ppm, a variable lipid peak at
0.9ppm and a less prominent Cho signal (Figures 1d and 2).
Control spectra obtained from skeletal muscle showed a prominent
creatine peak (only weakly present in tumour spectra) and a
modest Cho signal (Figure 3).
A C
B D Cho
Cho
ML ML
4 3 2 1 ppm 4 3 2 1 ppm
Figure 1 (A,C) Proton density-weighted MR images of two representative xenografts two (A) and three (C) weeks after cell inoculation, respectively.
Scale bars¼10mm. (B)
1H MRS spectrum from tumour in A. The selected VOI is indicated by a rectangle. Cho-containing compounds dominate the
spectrum. ML signals are also seen. TE¼20ms, 128 averages. (D)
1H MRS spectrum from large tumour seen in C. The VOI (rectangle in C) includes
tumour tissue with variable signal intensity. There is a weak Cho signal while MLs dominate. TE¼20ms, 128 averages. B and D are not shown to scale.
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sMorphology and tumour viability
Small tumours (Vo1.5ml) generally showed a dense and mostly
viable appearance on macroscopic examination while larger
tumours were mainly necrotic and haemorrhagic. These macro-
scopic findings were corroborated to microscopic analyses (Figure
4A–F). Microscopically viable tumour regions had the character-
istic appearance of poorly differentiated neuroblastoma (Figure
4A,B) (Shimada et al, 1999b). In nonviable areas, HE staining
demonstrated a diffuse type of cell death with necrosis, apoptosis,
haemorrhage and infiltrating inflammatory cells (Figure 4C).
Nonviable areas were strongly TUNEL positive (Figure 4D). The
proliferation index in viable tumour areas showed little variation
(LI¼3074%) between tumours, irrespective of treatment or
overall tumour viability (data not shown).
Angiostatic treatment
Histological examination of tumours from animals treated with
TNP-470 demonstrated a characteristic appearance with perivas-
cular cuffs of viable tumour cells embedded in nonviable areas
(Figure 4E,F). This was not observed in untreated tumours. When
compared to tumour volume, a tendency for lower viable fraction
in the treatment group was observed (Figure 5B). TNP-470-treated
tumours did not differ from untreated tumours of corresponding
size on appearance on MRI. Comparison of tumour volumes
between treatment and control groups on day 10 from tumour take
did not show any significant difference between the two groups
(data not shown).
Metabolic findings in relation to tumour characteristics
The ML/Cho ratio was significantly correlated with tumour volume
for both treated and untreated tumours (r¼0.75, Po0.05 and
r¼0.73, Po0.05, respectively) (Figure 5A). In the treatment group
ML/Cho ratios increased faster with tumour volume than in
untreated animals (Po0.05). Viable tumour fraction was nega-
tively correlated to tumour volume in untreated animals (r¼0.88,
Po0.001) (Figure 5B). In treated animals there was a tendency
towards a similar correlation (P¼0.058). Comparison with
histological findings revealed a significant inverse correlation
between the ML/Cho ratio and the viable tumour cell fraction
(r¼ 0.86, Po0.001) (Figure 6). This relation was valid for both
treated and untreated tumours. There was no correlation between
cell proliferation (Ki-67 index) and ML/Cho ratio (data not
shown).
ML (CH2)
ML (CH3)
Cho
Cho
Cho
ML
ML
Lac
Lac
C
B
A
TE = 135 ms
TE = 200 ms
TE = 20 ms
ppm
ppm
0 1 2 3 4
0 1 2 3 4
ppm
0 1 2 3 4
Figure 2 (A–C) TE dependence of spectra obtained from a largely
necrotic xenograft. (A): TE¼20ms. MLs dominate over a large range of
chemical shifts (0–3ppm) and obscure the Lac doublet resonance at
1.33ppm. (B)T E¼135ms. MLs have been reduced by faster T2 relaxation
to the level of Cho. Interference of Lac (inverse at 135ms) with residual
lipid resonances is clearly seen. (C)T E¼200ms. Relaxation differentiation
on long T2 metabolites (Cho, Lac). The fast relaxing ML signal has vanished
exhibiting the lactate doublet (antiphase dispersion lines).
Cho
Cre
Lip
ML
TE = 20 ms
ppm
0 1 2 3 4
Figure 3 Control spectra from skeletal muscle in a nude rat. The
resonance of creatine/phosphocreatine (Cre) at 3.0ppm was not
detectable in neuroblastomas. Cho¼choline, Lip¼lipids. TE¼20ms, 64
averages.
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sDISCUSSION
Noninvasive methods that allow repeated evaluation of tumour
status and response to therapy could improve efforts to
individualise treatment of cancer patients. Proton magnetic
resonance spectroscopy is emerging as a highly useful tool for
this purpose (Hakumaki et al, 2002; Kauppinen, 2002). In the
present work, we evaluated the relevance of MLs and Cho-
containing compounds detected in vivo by
1H MRS in a xenograft
model of human neuroblastoma. We found that the ML
(methylene)/Cho ratio constitutes a noninvasive measure of the
viable tumour fraction in this tumour model.
Only a few previous studies employing
1H MRS in neuroblas-
toma have been reported. Intense creatine and Cho signals were
found in
1H MRS spectra from perchloric extracts of neuroblas-
toma cells. (Florian et al, 1995). When neuroblastoma cells were
implanted in rat brain, a prominent Cho peak but no creatine was
detected in vivo with
1H MRS (Gyngell et al, 1994). MLs were not
analysed in these previous studies because of the extraction
procedure and TE employed, respectively.
Conventional MRI may detect necrosis in xenograft tumours
and was suggested as a marker of treatment response (Jakobsen
et al, 1995). However, necrosis as a possible in vivo marker of
successful treatment may be too unspecific as it frequently occurs
spontaneously in rapidly growing solid tumours. Furthermore, in
some tumour types, a high necrotic fraction was found to correlate
to worse outcome (Bjornsson et al, 1993; Pierallini et al, 1998). In
neuroblastomas, focal necrosis and haemorrhage are common
(Shimada et al, 1999a). We observed that neuroblastoma
xenografts developed extensive areas of necrosis and haemorrhage
during spontaneous growth (Figure 4). Therefore, we suggest that
assessment of the viable tumour fraction would likely be a more
accurate indicator of treatment response in neuroblastoma than
necrosis alone. Several investigators have demonstrated an
accumulation of MLs in areas of apoptosis/necrosis (Kuesel et al,
1996; Negendank and Sauter, 1996). Furthermore, in vitro studies
have shown that the ratio of the methylene (CH2) lipid resonance
(at 1.3ppm) to the methyl (CH3) resonance (at 0.9ppm) is
correlated to the percentage of apoptotic lymphoblasts after
doxorubicin treatment (Blankenberg et al, 1997). This finding
was recently confirmed using a human cervical carcinoma HeLa
cell system (Bezabeh et al, 2001). In the present study, we found
strong ML signals in large, highly necrotic tumours. However,
although less prominent, MLs were also detected in a subset of
viable non-necrotic tumours. Thus, in the present work MLs did
not per se indicate cell death. Consequently, events other than
apoptosis or necrosis may also be responsible for the lipid
resonances at 0.7–1.5ppm. This is in accordance with previous
reports demonstrating the presence of MLs in viable tumour areas
(Kuesel et al, 1994; Negendank and Sauter, 1996). Recently, we
performed
1H spectroscopic investigations of a panel of human
neuroblastoma cell lines in culture and found prominent ML
signals in viable cells (Lindskog et al, unpublished observation).
This observation is in line with the finding of ML droplets inside
growth-compromised, but viable, glioma cells (Barba et al, 1999).
Furthermore, in activated lymphocytes the amount of MRS-visible
lipids correlates with the proportion of cells in late S and G phase
(Veale et al, 1997). To clarify the biological significance of lipid
resonances, further studies aiming at linking factors such as cell
cycle distribution and tumour microenvironment (oxygenation,
nutrient supply and pH) to the dynamics of
1H MRS visible lipids
may be required.
Phosphocholine (PCho) is one of the major contributors to the
Cho resonance observed in
1H MRS spectra (Bhakoo et al, 1996;
Ackerstaff et al, 2001). The PCho concentration was shown to
correlate with the number of cells in S phase in a xenograft model
of breast cancer (Smith et al, 1991). In human astrocytoma the
Cho/crea time ratio correlates with proliferation index (Ki-67),
while the NAA/Cho ratio is inversely correlated with Ki-67
(Tamiya et al, 2000). Thus, it was suggested that the Cho signal
reflects cellular proliferation in these tumours. In our present
study, neither creatine nor NAA signals were unequivocally
accessible for spectroscopic analysis, nor were we able to show
any correlation between ML/Cho ratio and proliferative activity
Figure 4 (A) Overview of small, homogeneous tumour (HE). (B) Same tumour as in A (TUNEL and HE). Apoptotic cells brown (arrows). Cell
undergoing mitosis is marked with arrowhead. (C) Large untreated tumour with extensive central necrosis (CN) and a peripheral viable tumour tissue (VT)
(HE); (D) Same tumour as in C (TUNEL). (E) Overview of a tumour treated with TNP-470 (HE). Note multiple small round perivascular cuffs of tumour
cells surrounded by extensive necrosis and haemorrhage. (F) Same tumour as in E (TUNEL). Scale bar¼2mm applies to A and C. Scale bar in B¼25mm,
in D¼500mm, in E¼1mm, in F¼250mm, respectively.
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s(Ki-67). The antiangiogenic compound TNP-470 is an inhibitor of
endothelial cells (Castronovo and Belotti, 1996) and has been
shown to reduce the growth of neuroblastoma xenografts, causing
increased necrosis and apoptosis (Wassberg et al, 1997; Katzen-
stein et al, 1999). In experimental studies of antiangiogenic drugs,
tumour volume measurements have generally been employed for
in vivo assessment of treatment efficacy. Figure 5A shows that ML/
Cho ratios of both treated and untreated tumours correlate
significantly with tumour volume. Further, the stronger increase in
ML/Cho ratio as a function of tumour volume in treated tumours
suggests a decreased viability. This is verified in Figure 5B. Based
on these observations, and since measurement of tumour volume
may include both viable and necrotic areas, we suggest that
spectroscopic information could usefully complement volume
measurements for the evaluation of experimental treatment in
neuroblastoma.
In the present work, we evaluated the possibility of noninvasive
detection of early effects in response to TNP-470 in experimental
neuroblastomas, using
1H MRS. After 10 days of treatment, there
was no significant difference in tumour volume between the two
groups. We could, however, detect higher ML/Cho ratios in
relation to tumour volume in treated tumours (Figure 5A).
Concomitantly, marked histological changes were seen in TNP-
470-treated tumours (Figure 4E,F) similar to those previously
reported (Wassberg et al, 1997). Taken together, our observations
suggest that the higher ML/Cho ratios detected after short-term
TNP-470 treatment indicate early antitumour effects as reflected in
the histological appearance. The partial overlap between the
treatment and the control group in tumours smaller than 1ml and
with ML/Cho ratios below 0.5 (Figure 5A) may be explained by the
fact that these tumours (two treated and two untreated) were
highly viable. This suggests the existence of two ‘poor responders’
in the treatment group. It needs to be further explored as to
whether
1H MRS could serve as a noninvasive method to monitor
efficacy in longitudinal studies with antiangiogenic drugs.
The SH-SY5Y xenograft model employed in this study is a well-
characterized and highly reproducible in vivo model of poorly
differentiated human neuroblastoma (Nilsson et al, 1993; Ponthan
et al, 2001). Caution should however be taken not to generalise our
findings to all neuroblastoma tumours since this is a highly
heterogeneous disease. To further address a potential role of
1H
MRS for the monitoring of neuroblastoma biology and, impor-
tantly, for validating the efficacy of novel antitumour therapies,
additional studies are needed. Performing repeated in vivo
1H MRS
examinations, we recently observed increases in ML/Cho ratios in
neuroblastoma xenografts during chemotherapy (Lindskog et al,
unpublished observation). In the present paper, we provide
evidence that the ML/Cho ratio inversely correlates to tumour
viability. Hence, we suggest that
1H MRS could be a tool for
monitoring the treatment of neuroblastoma in children by
repeated examinations during the course of therapy.
In conclusion, we have shown that the viable tumour fraction
can be accurately estimated in vivo with
1H MRS in a model of
human neuroblastoma. Our findings also suggest that the ML/Cho
ratio may be valuable as a noninvasive surrogate marker to detect
response to experimental therapy in neuroblastoma.
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Figure 5 (A) The ML/Cho ratio (here shown as log value) correlated
significantly to tumour volume for treated (open circles, Po0.05) and
untreated (solid circles, Po0.05) tumours. The regressions of control and
treatment groups were significantly different (Po0.05). (B) In untreated
tumours, viable fraction correlated inversely with tumour volume
(r¼ 0.88, Po0.05). A comparable trend was also seen for treated
tumours, though with steeper slope (r¼ 0.68, P¼0.058).
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Figure 6 Significant inverse correlation between ML/Cho-ratio and
viable tumour fraction in human neuroblastoma xenografts (r¼ 0.86,
Po0.001) (data pooled from TNP and control groups).
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